The mRNA levels of α-Sma and Col1a1 decreased in NASH mice treated with HLSCs at different time points with a statistically significant reduction observed in NASH mice injected at week 2 (Figure 5(e)). Here, ACTA1 is linked to metabolic dysfunction-associated steatohepatitis.